Tenax Therapeutics, Inc.
TENX
$6.00
-$0.04-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 321.95% | 358.64% | 64.55% | 43.30% | 29.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 221.22% | 190.05% | 118.34% | 118.14% | 196.96% |
| Operating Income | -221.22% | -190.05% | -118.34% | -118.14% | -196.96% |
| Income Before Tax | -203.41% | -173.97% | -94.27% | -100.84% | -223.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -203.41% | -173.97% | -94.27% | -100.84% | -223.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -203.41% | -173.97% | -94.27% | -100.84% | -223.15% |
| EBIT | -221.22% | -190.05% | -118.34% | -118.14% | -196.96% |
| EBITDA | -- | -- | -118.62% | -118.15% | -197.04% |
| EPS Basic | -43.22% | 90.87% | 98.35% | 97.17% | 54.38% |
| Normalized Basic EPS | -43.23% | 90.87% | 98.36% | 97.17% | 54.38% |
| EPS Diluted | -43.22% | 90.87% | 98.35% | 97.17% | 54.38% |
| Normalized Diluted EPS | -43.23% | 90.87% | 98.36% | 97.17% | 54.38% |
| Average Basic Shares Outstanding | 111.85% | 2,900.98% | 11,712.01% | 6,993.90% | 608.21% |
| Average Diluted Shares Outstanding | 111.85% | 2,900.98% | 11,712.01% | 6,993.90% | 608.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |